BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ahmed AR, Hombal SM. Cyclophosphamide (Cytoxan). A review on relevant pharmacology and clinical uses. J Am Acad Dermatol. 1984;11:1115-1126. [PMID: 6392368 DOI: 10.1016/s0190-9622(84)80193-0] [Cited by in Crossref: 116] [Cited by in F6Publishing: 22] [Article Influence: 3.2] [Reference Citation Analysis]
Number Citing Articles
1 Teicher BA, Herman TS, Holden SA, Cathcart KN. The effect of fluosol-DA and oxygenation status on the activity of cyclophosphamide in vivo. Cancer Chemother Pharmacol 1988;21:286-91. [PMID: 3131033 DOI: 10.1007/BF00264193] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
2 Noori S, Rezaei Tavirani M, Deravi N, Mahboobi Rabbani MI, Zarghi A. Naringenin Enhances the Anti-Cancer Effect of Cyclophosphamide against MDA-MB-231 Breast Cancer Cells Via Targeting the STAT3 Signaling Pathway. Iran J Pharm Res 2020;19:122-33. [PMID: 33680016 DOI: 10.22037/ijpr.2020.113103.14112] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
3 Khan S, Jena GB. Effect of sodium valproate on the toxicity of cyclophosphamide in the testes of mice: influence of pre- and post-treatment schedule. Toxicol Int 2013;20:68-76. [PMID: 23833441 DOI: 10.4103/0971-6580.111562] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
4 Ramirez DA, Collins KP, Aradi AE, Conger KA, Gustafson DL. Kinetics of Cyclophosphamide Metabolism in Humans, Dogs, Cats, and Mice and Relationship to Cytotoxic Activity and Pharmacokinetics. Drug Metab Dispos 2019;47:257-68. [PMID: 30567881 DOI: 10.1124/dmd.118.083766] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
5 Zhang L, Marciano-Cabral F, Bradley SG. Effects of cyclophosphamide and a metabolite, acrolein, on Naegleria fowleri in vitro and in vivo. Antimicrob Agents Chemother 1988;32:962-5. [PMID: 3190198 DOI: 10.1128/AAC.32.7.962] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
6 Luo D, Carter KA, Miranda D, Lovell JF. Chemophototherapy: An Emerging Treatment Option for Solid Tumors. Adv Sci (Weinh) 2017;4:1600106. [PMID: 28105389 DOI: 10.1002/advs.201600106] [Cited by in Crossref: 202] [Cited by in F6Publishing: 200] [Article Influence: 40.4] [Reference Citation Analysis]
7 Mutasim DF. Autoimmune bullous dermatoses in the elderly: an update on pathophysiology, diagnosis and management. Drugs Aging 2010;27:1-19. [PMID: 20030429 DOI: 10.2165/11318600-000000000-00000] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
8 Afshari H, Nourbakhsh M, Salehi N, Mahboubi-Rabbani M, Zarghi A, Noori S. STAT3-mediated Apoptotic-enhancing Function of Sclareol Against Breast Cancer Cells and Cell Sensitization to Cyclophosphamide. Iran J Pharm Res 2020;19:398-412. [PMID: 32922496 DOI: 10.22037/ijpr.2020.112587.13843] [Reference Citation Analysis]
9 Hui MK, Wu WK, Shin VY, So WH, Cho CH. Polysaccharides from the root of Angelica sinensis protect bone marrow and gastrointestinal tissues against the cytotoxicity of cyclophosphamide in mice. Int J Med Sci 2006;3:1-6. [PMID: 16421623 DOI: 10.7150/ijms.3.1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 1.4] [Reference Citation Analysis]
10 Sato H, Shirai T, Fujii H, Ishii T, Harigae H. Cyclophosphamide-associated enteritis presenting with severe protein-losing enteropathy in granulomatosis with polyangiitis: A case report. World J Gastroenterol 2021; 27(20): 2657-2663 [PMID: 34092982 DOI: 10.3748/wjg.v27.i20.2657] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Jewkes BC, Gomella MG, Lowry ET, Benner JA, Delay ER. Cyclophosphamide-Induced Disruptions to Appetitive Qualities and Detection Thresholds of NaCl: Comparison of Single-Dose and Dose Fractionation Effects. Chem Senses 2018;43:399-410. [PMID: 29788185 DOI: 10.1093/chemse/bjy026] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
12 Mutasim DF. Autoimmune bullous dermatoses in the elderly: diagnosis and management. Drugs Aging 2003;20:663-81. [PMID: 12831291 DOI: 10.2165/00002512-200320090-00004] [Cited by in Crossref: 22] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
13 Mustafi S, Sinha R, Hore S, Sen S, Maity S, Ghosh P. Pulse therapy: Opening new vistas in treatment of pemphigus. J Family Med Prim Care 2019;8:793-8. [PMID: 31041203 DOI: 10.4103/jfmpc.jfmpc_114_19] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Sharma SK, Jain S, Bahl P, Potturi P, Rathi M, Naidu S, Sachdeva N, Dhir V, Jain S. Ovarian dysfunction with moderate-dose intravenous cyclophosphamide (modified NIH regimen) and mycophenolate mofetil in young adults with severe lupus: a prospective cohort study. Arthritis Res Ther 2020;22:189. [PMID: 32799907 DOI: 10.1186/s13075-020-02292-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 de Jonge ME, Huitema AD, Rodenhuis S, Beijnen JH. Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet. 2005;44:1135-1164. [PMID: 16231966 DOI: 10.2165/00003088-200544110-00003] [Cited by in Crossref: 226] [Cited by in F6Publishing: 198] [Article Influence: 15.1] [Reference Citation Analysis]
16 Diehl R, Ferrara F, Müller C, Dreyer AY, McLeod DD, Fricke S, Boltze J. Immunosuppression for in vivo research: state-of-the-art protocols and experimental approaches. Cell Mol Immunol 2017;14:146-79. [PMID: 27721455 DOI: 10.1038/cmi.2016.39] [Cited by in Crossref: 48] [Cited by in F6Publishing: 46] [Article Influence: 9.6] [Reference Citation Analysis]
17 Kennedy R, Groepper D, Tagen M, Christensen R, Navid F, Gajjar A, Stewart CF. Stability of cyclophosphamide in extemporaneous oral suspensions. Ann Pharmacother 2010;44:295-301. [PMID: 20103616 DOI: 10.1345/aph.1M578] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
18 Mallick S, Barua A, Paul G, Banerjee SN. Novel combination of 2-methoxyestradiol and cyclophosphamide enhances the antineoplastic and pro-apoptotic effects on S-180 ascitic tumour cells. J Cell Commun Signal 2018;12:467-78. [PMID: 28795302 DOI: 10.1007/s12079-017-0404-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
19 Barry RJ, Nguyen QD, Lee RW, Murray PI, Denniston AK. Pharmacotherapy for uveitis: current management and emerging therapy. Clin Ophthalmol 2014;8:1891-911. [PMID: 25284976 DOI: 10.2147/OPTH.S47778] [Cited by in Crossref: 4] [Cited by in F6Publishing: 21] [Article Influence: 0.6] [Reference Citation Analysis]
20 Kar PK. RECENT TRENDS IN THE MANAGEMENT OF PEMPHIGUS VULGARIS. Med J Armed Forces India 1998;54:243-6. [PMID: 28790567 DOI: 10.1016/S0377-1237(17)30554-3] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
21 Bhat N, Kalthur SG, Padmashali S, Monappa V. Toxic Effects of Different Doses of Cyclophosphamide on Liver and Kidney Tissue in Swiss Albino Mice: A Histopathological Study. Ethiop J Health Sci. 2018;28:711-716. [PMID: 30607087 DOI: 10.4314/ejhs.v28i6.5] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
22 Teicher BA. Hypoxia and drug resistance. Cancer Metastasis Rev. 1994;13:139-168. [PMID: 7923547 DOI: 10.1007/bf00689633] [Cited by in Crossref: 385] [Cited by in F6Publishing: 124] [Article Influence: 14.3] [Reference Citation Analysis]